Home | RheumNow

Recent News

Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner
Save

Jiha Lee, MD

Nov 02, 2026

At APLAR 2026 in Seoul, the OA special interest group offered a whirlwind overview of IA injectables from Dr. Gun-il Im (Dongguk University, Korea). The products fall into three tiers: symptom-modifying, biologic/regenerative and structure-oriented. The pipeline is encouraging, but the evidence is uneven and often thin.
Read Article

What's next for a patient with PsA and GI symptoms who failed a csDMARD? 🔊 Listen to Dr. Saakshi Khattri discuss this case and the data that shaped her treatment decision with Lindsay Tom, PA-C. Sponsored by AbbVie Medical Affairs + Health Impact. https://t.co/6fDS5WoSX5 https://t.co/PvoIKbk9xg

Individualized PsA Treatment With an IL-23i or a JAKi | RheumNow

Tocilizumab is effective in glucocorticoid-resistant adult-onset Still’s dz. 40 AOSD pts rx w/ TCZ (4-8 mg/kg q4wks). @12 mos clin remission 55%, 6 mos CID 62%, signif drops in CRP, ESR, ferritin & daily pred decr 91% (50 to 4.4 mg; p<0.001). TCZ retention 65%; MAS 7.5% & https://t.co/jtAxrz6ETd

Long term F/U of 80 systemic sclerosis pts Rx w/ autologous HSCT. W/ Med. 9.2 yrs F/U progression-free survival = 81%, 72% @5 yrs, & 60% @10 yrs. 18 pts died; death due to HSCT in 6%, SSc progression in 11%, CA in 2 (3%), serious infx 2 (3%), 34 (43%) maintained remission without https://t.co/l6RUf2Zqyw

FDA has approved the IL-23 inhibitor tildrakizumab (Ilumya) use in adults with active psoriatic arthritis (PsA), expanding the interleukin indications beyond moderate-to-severe plaque psoriasis. (Based on INSPIRE-1/2; >800 adults, 52-week RCTs) https://t.co/tCKZQwf74A https://t.co/Qffr1ZAMd7

Japanese retrospective cohort systemic sclerosis study shows adjunctive tofacitinib improved ower esophageal sphincter pressures (LESP). 50 SSc pts w/ esophageal Sxs Rx w/ Tofa or PBO x 24 wks. Tofa assoc w/ signif LESP increases & lower mRSS & IL-6 levels https://t.co/NNREBddiOi https://t.co/p6VujI8HWA

Tofacitinib and esophageal-related manifestations in systemic sclerosis: a retr…

Dr. Lisa Stamp highlights crucial pharmacologic implications of COL use for gout flares in pts w/ comorbidities: - Dose adjustment in CKD - Be mindful of potential drug interactions @RheumNow #APLAR2026 https://t.co/efA7ptFF7Y

https://x.com/RHEUMarampa/status/2116444133275627892/photo/1

AxSpA SIG : Baraliakos - inflammation drives fatty lesions producing damage and osteoblastic activity @RheumNow @APLAR2026 https://t.co/GDFSwt2IOm

Why phenotype OA? Mechanisms, course and treatment response vary. Three knees at the same Kellgren-Lawrence grade 2 can differ: post-meniscal varus pain, obesity with synovitis, or widespread tenderness etc. X-ray grade alone misses this. OA:SIG #APLAR26 @RheumNow https://t.co/RWtq3ORGwc

https://x.com/JihaRheum/status/2116079474475475321/photo/1

Mease : future therapy - Be-Bold H2H Bime vs Rizi, Sonelokimab, Izokibep, Deucra, Zaso, Ico, TL1Ainhib @RheumNow #APLAR2026 https://t.co/Rv5hwnQnDl

Prof. AHoi presented their study on ESR as potential source of risk info in SLE 48% discordance bet ESR & conv. serology Isolated ⬆️ESR levels showed ⬆️ assoc with dse activity and flare; risk increases further if combi ⬆️ESR+low c3/4+antidsDNA @RheumNow #APLAR2026 https://t.co/BvC0OZFjd5

Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested. https://t.co/kV4Y7tvpC8

Rituximab or Azathioprine for EGPA Maintenance? A French study has shown that rituximab is more effective than azathioprine at maintaining remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA) on chronic prednisone. https://t.co/UrHqPBVibn https://t.co/cpusNcpYWd

Rituximab or Azathioprine for EGPA Maintenance? | RheumNow

Grappa Symposium: Leung Obesity in PsA - done deal @RheumNow #APLAR2026 https://t.co/3YQT4kiPer

AxSpA+rash vs Axial PsA Kishimoto : two phenotypes of the same disease and to maximise specificity Axis study - imaging criteria = AxSpA phenotype @RheumNow #APLAR2026 https://t.co/UYFnA3AyUM

https://x.com/drpnash/status/2116402903040897383/photo/1

An important and relevant reminder from @rheumarhyme on AI use @RheumNow #APLAR2026 https://t.co/7Ratb6aQOD

https://x.com/RHEUMarampa/status/2116369684358684894/photo/1

AI can be helpful in manuscript creation As the author: > always verify the draft - allow time to check > take full responsibility of the content - review and revise the final manuscript @RheumNow #APLAR2026 https://t.co/cQsEtDc7z1

Case quiz: 38F fever, tetraparesis, hallucinations, slurred speech. Low C3, ANA 1:100, WBC 26,320, normal CSF/Ca/PTH. CT: basal ganglia calcification. Dx? Answer: SLE with Fahr syndrome (focal NPSLE) plus urosepsis. Keep infection in rheum Ddx. P#325 #APLAR26 @RheumNow https://t.co/Gsb8dquwHL

https://x.com/JihaRheum/status/2116329865196552649/photo/1

Dr. Poddubny on AI & machine learning in SpA AI has enabled the analysis of large data sets offering a support for clinical decision-making. Future directions? Making scans faster leading to rapid analysis Challenge: access to large, high quality data @RheumNow #APLAR2026 https://t.co/UhdjSRXtOv

Better drugs only help if patients can get them. In an APLAR PsA registry, 43% of lowest-GDP patients had not reached MDA and were not on a biologic or targeted DMARD. Coverage, reimbursement and social support needed, not just science. P#242 #APLAR26 @RheumNow https://t.co/Rms4QsbcII

https://x.com/JihaRheum/status/2116327499210842589/photo/1

Video

Podcasts

Individualized PsA Treatment With an IL-23i or a JAKi
Nov 02, 2026
DERM on RheumNow PODCAST (October 2026)
Oct 31, 2026
Mixed Drinks, Mixed Results (10.30.2026)
Oct 30, 2026
Advances and Challenges in Lupus Care: Insights from RheumNow Survey Findings
Oct 28, 2026

Submit your Rheumatology question or case here

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Sponsored by AbbVie Medical Affairs + Health Impact

Nov 01, 2026

In Part 2 of our PsA management series, Saakshi Khattri, MD, and Lindsay Tom, PA-C, discuss tailoring treatment for patients with multidomain PsA and how IL-23i and JAKi data guide their decisions

Read Post

Topics

Recent News

Intra-Articular Injections for Knee OA: Options, Evidence, and no Clear Winner
Save

Video

Podcasts

Therapeutic Updates

Individualized PsA Treatment With an IL-23i or a JAKi

Poster Hall

Long-Term Safety of a JAKi in Clinical Trial and Real-World Settings Across >21,000 Patient-Years

Daily Download

GLP-1 Receptor Agonists in Rheumatology

Do you get our email newsletter?